Stay updated with breaking news from Biosimilar Molecules. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The company said that this will be a significant jump from the R&D spending of Rs 310 crore it reported for FY22, which represented 9 per cent of its revenue for the year.
As per the latest Clinical Research Organisation (CLRO) Market Report by Frost & Sullivan (India), India is becoming an attractive destination for clinical and preclinical research outsourcing supported by quality scientific capability, the emergence of the biosimilars industry, increased demand for complex generics and availability of a large number of patient volunteers. A key player of the Indian CLRO market, Ahmedabad-based Veeda Clinical Research is all set to capitalise on the growing R&D budget of the global pharmaceutical firms. In conversation with BioSpectrum, Ajay Tandon, M...